DE69627817D1 - Pharmazeutische zubereitung, die fenofibrat und polyglykolisierte glyceride enthält - Google Patents

Pharmazeutische zubereitung, die fenofibrat und polyglykolisierte glyceride enthält

Info

Publication number
DE69627817D1
DE69627817D1 DE69627817T DE69627817T DE69627817D1 DE 69627817 D1 DE69627817 D1 DE 69627817D1 DE 69627817 T DE69627817 T DE 69627817T DE 69627817 T DE69627817 T DE 69627817T DE 69627817 D1 DE69627817 D1 DE 69627817D1
Authority
DE
Germany
Prior art keywords
pharmaceutical preparation
preparation containing
polyglycolized glycerides
containing fenofibrate
fenofibrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69627817T
Other languages
English (en)
Other versions
DE69627817T2 (de
DE69627817T3 (de
Inventor
M Deboeck
Philippe Baudier
J Maes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GALEPHAR P R Inc
Original Assignee
GALEPHAR P R Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23461583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69627817(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GALEPHAR P R Inc filed Critical GALEPHAR P R Inc
Application granted granted Critical
Publication of DE69627817D1 publication Critical patent/DE69627817D1/de
Publication of DE69627817T2 publication Critical patent/DE69627817T2/de
Publication of DE69627817T3 publication Critical patent/DE69627817T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE69627817T 1995-01-10 1996-01-10 Pharmazeutische zubereitung, die fenofibrat und polyglykolisierte glyceride enthält Expired - Lifetime DE69627817T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/370,883 US5545628A (en) 1995-01-10 1995-01-10 Pharmaceutical composition containing fenofibrate
US370883 1995-01-10
PCT/BE1996/000002 WO1996021439A1 (en) 1995-01-10 1996-01-10 Pharmaceutical composition containing fenofibrate and polyglycolized glycerides

Publications (3)

Publication Number Publication Date
DE69627817D1 true DE69627817D1 (de) 2003-06-05
DE69627817T2 DE69627817T2 (de) 2004-02-26
DE69627817T3 DE69627817T3 (de) 2008-02-28

Family

ID=23461583

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69627817T Expired - Lifetime DE69627817T3 (de) 1995-01-10 1996-01-10 Pharmazeutische zubereitung, die fenofibrat und polyglykolisierte glyceride enthält

Country Status (8)

Country Link
US (1) US5545628A (de)
EP (1) EP0801562B2 (de)
JP (1) JP4322313B2 (de)
AU (1) AU4380896A (de)
CA (1) CA2210985C (de)
DE (1) DE69627817T3 (de)
ES (1) ES2200048T5 (de)
WO (1) WO1996021439A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2748209B1 (fr) * 1996-05-06 1998-06-05 Adir Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs
WO1998007414A1 (en) 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
BE1011363A3 (fr) * 1997-09-11 1999-08-03 Smb Technology Capsules semi-solides autoemulsionnables matricielles a action prolongee.
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
PT996429E (pt) * 1997-10-27 2003-06-30 Merck Patent Gmbh Solucoes e dispersoes no estado solido de farmacosfracamente soluveis em agua
AU1809499A (en) * 1997-12-10 1999-06-28 Awadhesh K. Mishra Self-emulsifying fenofibrate formulations
JP2002516267A (ja) 1998-05-29 2002-06-04 アールティーピー・ファーマ・インコーポレーテッド 熱的に保護された微粒子組成物及びその最終蒸気滅菌
FR2781373B1 (fr) * 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
FR2782006B1 (fr) 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
DE69915084T2 (de) * 1998-09-30 2004-07-22 Warner-Lambert Co. Llc Methode zur vermeidung oder verzögerung von katheterbedingter gefässrückbildung
PL201578B1 (pl) 1998-11-20 2009-04-30 Skyepharma Canada Inc Stała terapeutyczna postać dawkowania nierozpuszczalnego lub słabo rozpuszczalnego w wodzie związku
US7014864B1 (en) 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6838091B2 (en) * 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
CA2270306C (en) * 1999-04-27 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
US6368620B2 (en) * 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
AU2001257115B2 (en) 2000-04-20 2005-01-27 Rtp Pharma Inc. Improved water-insoluble drug particle process
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
US6534088B2 (en) * 2001-02-22 2003-03-18 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
CA2456732C (en) * 2001-08-07 2012-10-30 Galephar M/F Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
CN1288764C (zh) * 2002-09-17 2006-12-06 日本电信电话株式会社 半导体光调制器和具有光调制器的激光器
US7186519B2 (en) * 2002-11-13 2007-03-06 Trustees Of Dartmouth College Method for detecting intracellular cholesterol
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US20070160663A1 (en) * 2003-08-05 2007-07-12 Galephar Pharmaceutical Research, Inc. Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
LT1765292T (lt) 2004-06-12 2018-01-10 Collegium Pharmaceutical, Inc. Nuo piktnaudžiavimo apsaugotos vaistų formos
US8026281B2 (en) 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
EA014420B1 (ru) * 2004-12-06 2010-12-30 Релайэнт Фармасьютикалз, Инк. Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
US20060188529A1 (en) * 2004-12-06 2006-08-24 George Bobotas Stable compositions of fenofibrate with fatty acid esters
KR20070108945A (ko) * 2005-03-08 2007-11-13 릴라이언트 파마슈티컬스 인코퍼레이티드 스타틴과 오메가-3 지방산 및 그 조합물을 이용한 치료
WO2006107316A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or peg/poloxamer
BRPI0609497A2 (pt) * 2005-03-30 2010-04-13 Teva Pharma formulações aprimoradas de fenofibrato
JP2013047282A (ja) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
JP5186159B2 (ja) * 2006-08-31 2013-04-17 あすか製薬株式会社 フェノフィブラート含有組成物
US9180110B2 (en) 2007-02-26 2015-11-10 Wockhardt Ltd. Pharmaceutical compositions of fenofibrate
WO2008104846A2 (en) * 2007-02-26 2008-09-04 Wockhardt Research Centre Pharmaceutical compositions of fenofibrate
RU2011103066A (ru) * 2008-07-03 2012-08-10 Панацеа Биотек Лимитед (In) Состав фенофибрата с улучшенной биодоступностью при пероральном введении
US8524280B2 (en) * 2008-12-15 2013-09-03 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2011000126A1 (zh) * 2009-06-29 2011-01-06 Liu Yu 脂溶性药物组合物、制备方法及其用途
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP3046551B1 (de) 2013-09-18 2020-08-05 Georgetown University Behandlung von neurodegenerativer erkrankung mit fenofibrate und analoga davon
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416877A (en) * 1979-02-13 1983-11-22 Symphar S.A. Anti-atherosclerotic pharmaceutical compositions containing diphosphonate compounds
GB8524421D0 (en) † 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
FR2627696B1 (fr) † 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
WO2003013500A1 (en) † 2001-08-07 2003-02-20 Laboratoires Smb Sa Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it

Also Published As

Publication number Publication date
WO1996021439A1 (en) 1996-07-18
EP0801562B2 (de) 2007-08-08
JP4322313B2 (ja) 2009-08-26
DE69627817T2 (de) 2004-02-26
AU4380896A (en) 1996-07-31
DE69627817T3 (de) 2008-02-28
JPH10511959A (ja) 1998-11-17
EP0801562A1 (de) 1997-10-22
US5545628A (en) 1996-08-13
ES2200048T3 (es) 2004-03-01
CA2210985A1 (en) 1996-07-18
EP0801562B1 (de) 2003-05-02
ES2200048T5 (es) 2008-02-16
CA2210985C (en) 2007-01-09

Similar Documents

Publication Publication Date Title
DE69627817D1 (de) Pharmazeutische zubereitung, die fenofibrat und polyglykolisierte glyceride enthält
DE69626397T2 (de) Darifenacin enthaltende pharmazeutische zubereitungen
DE69525148D1 (de) Pharmazeutische formulierung
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
ATE183495T1 (de) 6-dimethylaminomethyl-1-phenyl-cyclo- hexanverbindungen als pharmazeutische wirkstoffe
DE59604226D1 (de) 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-olverbindungen als pharmazeutische Wirkstoffe
DE69629755D1 (de) Irbesartanhaltiges Arzneimittel
DK0754061T3 (da) Ny oral farmaceutisk doseringsform
KR970012150U (ko) 의약 및 식품용 하드 공 캅셀
FI932655A (fi) Imidatderivat av farmaceutiskt anvaendbara antikonvulsiva sulfamat
DE69726015D1 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
EE200000395A (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm
HU9503835D0 (en) Soft gelatin pharmaceutical dosage form
ATE288419T1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
BR9610396A (pt) Formulação farmacêutica
ATE228829T1 (de) Tablette mit gesteuerter freisetzung
DE59604457D1 (de) Zuckertenside und Fettsäurepartialglyceride enthaltende kosmetische und/oder pharmazeutische Zubereitungen
DE69614407D1 (de) Pharmazeutische zusammensetzungen
DE69622391D1 (de) Missbrauch sichtbar machende pharmazeutische dosisform
ATE269695T1 (de) Pharmazeutische pellets
FI973230A (fi) Uusi farmaseuttinen formulaatio
DE19681529D2 (de) Pharmazeutische Darreichungsform
DE9414607U1 (de) Parfümkapsel
KR950006390U (ko) 1회용 캡슐비누
BR9603673A (pt) Preparado de combinação farmacêutica compreendendo cetoprofeno

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings